Jacqueline D. Reeves / Cynthia A. Derdeyn (eds.)

Entry Inhibitors in HIV Therapy

Herausgegeben:Reeves, Jacqueline D.; Derdeyn, Cynthia A.

• Gebundenes Buch

Produktbeschreibung

Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors, appealing to both the clinician and basic research scientist. A unique overview of obstacles and accomplishments is presented. The book features chapters that explain the challenges of high sequence diversity in the viral envelope gene for the development and use of entry inhibitors, the clinical utility of virus phenotyping, the development of this class of inhibitors as microbicidal therapy, and the success story of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field.

Produktdetails

• Milestones in Drug Therapy
• Verlag: Birkhäuser / Birkhäuser Basel / Springer, Basel
• Artikelnr. des Verlages: 11672432, 978-3-7643-7782-3
• 2007
• Seitenzahl: 220
• Erscheinungstermin: 22. Juni 2007
• Englisch
• Abmessung: 250mm x 175mm x 18mm
• Gewicht: 504g
• ISBN-13: 9783764377823
• ISBN-10: 3764377828
• Artikelnr.: 22430096

Autorenporträt

Jacqueline D. Reeves, Monogram Biosciences, San Francisco, CA, USA / Cynthia A. Derdeyn, Emory University, Atlanta, GA, USA

Inhaltsangabe

to entry inhibitors in the management of HIV infection.- The challenge of HIV sequence diversity in the envelope glycoprotein.- Attachment of human immunodeficiency virus to cells and its inhibition.- Inhibitors that target gp120-CD4 interactions.- Inhibitors that target gp120 interactions with coreceptor.- Inhibitors that target fusion.- HIV-1 entry inhibitors as microbicides.- Entry inhibition of HIV-1 subtype C isolates.- The utility of coreceptor typing in the clinic.- Future clinical prospects for entry inhibitors.- Enfuvirtide: from basic science to FDA approval.- Targets for drug development - past and present.

---

to entry inhibitors in the management of HIV infection.- The challenge of HIV sequence diversity in the envelope glycoprotein.- Attachment of human immunodeficiency virus to cells and its inhibition.- Inhibitors that target gp120-CD4 interactions.- Inhibitors that target gp120 interactions with coreceptor.- Inhibitors that target fusion.- HIV-1 entry inhibitors as microbicides.- Entry inhibition of HIV-1 subtype C isolates.- The utility of coreceptor typing in the clinic.- Future clinical prospects for entry inhibitors.- Enfuvirtide: from basic science to FDA approval.- Targets for drug development — past and present.